Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of livmoniplimab + budigalimab versus chemotherapy in metastatic urothelial carcinoma
jRCT2021240039Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of livmoniplimab and budigalimab in transitional cell carcinoma (TCC) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Overall Survival. Started Jan 2025; status: active, not recruiting.
02
Drugs
livmoniplimabbudigalimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2021240039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240039.